Zacks Investment Research upgraded shares of Eleven Biotherapeutics Inc (NASDAQ:EBIO) from a sell rating to a hold rating in a research note issued to investors on Tuesday.
According to Zacks, “Eleven Biotherapeutics, Inc. is engaged in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its principal preclinical product candidate consist of EBI-005, a novel IL-1 receptor antagonist for the topical treatment of dry eye disease and allergic conjunctivitis, EBI-029, a novel inhibitor of the cytokine IL-6 for the treatment of certain retinal diseases, such as DME and EBI-028, a novel inhibitor of the cytokine IL-17 for the treatment of uveitis. Eleven Biotherapeutics, Inc. is based in Cambridge, United States. “
Shares of Eleven Biotherapeutics (NASDAQ:EBIO) traded up 0.68% during trading on Tuesday, hitting $1.47. The company had a trading volume of 141,422 shares. The company has a market capitalization of $22.63 million, a P/E ratio of 9.74 and a beta of 3.69. Eleven Biotherapeutics has a 52 week low of $1.03 and a 52 week high of $5.97. The stock’s 50-day moving average price is $1.88 and its 200 day moving average price is $2.06.
Eleven Biotherapeutics (NASDAQ:EBIO) last posted its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter. Eleven Biotherapeutics had a negative net margin of 16.51% and a negative return on equity of 25.00%. The business had revenue of $0.43 million for the quarter. On average, equities research analysts forecast that Eleven Biotherapeutics will post ($1.75) earnings per share for the current year.
A number of large investors have recently modified their holdings of EBIO. Geode Capital Management LLC raised its stake in shares of Eleven Biotherapeutics by 0.6% in the first quarter. Geode Capital Management LLC now owns 47,187 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 300 shares during the period. Oxford Asset Management purchased a new stake in shares of Eleven Biotherapeutics during the fourth quarter worth $343,000. Finally, Vanguard Group Inc. raised its stake in shares of Eleven Biotherapeutics by 45.1% in the first quarter. Vanguard Group Inc. now owns 175,850 shares of the biopharmaceutical company’s stock worth $386,000 after buying an additional 54,694 shares during the period. 24.75% of the stock is owned by institutional investors and hedge funds.
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eleven Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.